

# **Local Chamber Munich**

File no: **ACT\_459916/2023** 

Nature of the action: **Infringement action** 

# Procedural order No. ORD\_556750/2023 UPC\_CFI\_14/2023 of the Court of First Instance of the Unified Patent Court, issued on: 28/07/2023

## **KLÄGER**

1) Amgen Inc.

(Plaintiff) - One Amgen Center Drive, Mail- Stop 28-2-C - 91320-1799 -Thousand Oaks - US Represented by: Johannes Heselberger

### **CONDITIONED**

1) Sanofi-Aventis Germany GmbH
(Defendant) - Industriepark Höchst,
Brüningstraße 50 - 65926 - Frankfurt am
Main - DE

Represented by: Niels Hölder

2) Sanofi-Aventis Groupe S.A.

(Defendant) - 54 rue La Boétie - 75008 - Paris - FR Represented by: Niels Hölder

3) Sanofi Winthrop Industrie S.A. (Defendant) - 82 avenue Raspail - 94250 -

Represented by: Niels Hölder

Gentilly - FR

4) Regeneron Pharmaceuticals Inc. (Defendant) - 81 Columbia Turnpike -12144 - Rensselaer - US Represented by: Niels Hölder

## **PATENT AT ISSUE**

Patent no.	Owner
EP3666797	Amgen Inc.

### **DECISIVE JUDGE**

**COMPOSITION OF THE PANEL - RAPPORTEUR** 

Presiding Judge

**Matthias Zigann** 

PROCEDURAL LANGUAGE: German

### **REASONS FOR THE ORDER**

The plaintiff withdrew its motion to sever the proceedings against the fourth defendant in a written statement dated 27 July 2023.

After successful service on the 4th defendant, the reason for the requested severance ceased to exist.

### **ARRANGEMENT**

- 1. The proceedings against the 4th defendant shall not be severed.
- 2. The provisional order of 17.07.2023 is therefore invalid.

Dr Zigann Presiding Judge and Rapporteur